

PRESS RELEASE
11 November 2013



BioInvent granted US patent for the F.I.R.S.T.[™] antibody screening technology

Lund, Sweden – 11 November, 2013 – BioInvent International AB (OMXS: BINV) today announces that it has been granted a US patent for its antibody and concomitant target discovery technology F.I.R.S.T.[™].

Traditional drug discovery methods involve the identification of drugs candidates that bind to known disease targets. The F.I.R.S.T.[™] technology is a novel and unique discovery method, which allows for antibodies and disease targets to be identified simultaneously.

BioInvent has used F.I.R.S.T.[™] successfully in several proprietary discovery projects and offers F.I.R.S.T.[™] as well as traditional antibody discovery screening to commercial partners.

“With billions of binders available in the libraries and state-of-the-art *in vitro* and *in vivo* cancer and immunological assays, we can discover antibodies with the very best properties for onward development.” **Said Björn Frendeus, VP Preclinical Research at BioInvent.**

-- END --

To the editors:

About BioInvent

BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer. The Company's pipeline currently includes three product candidates for the treatment of cancer.

The company has unique expertise in antibody drug development from initial concept to late clinical phase. The antibody library n-CoDeR[®] and the screening tool F.I.R.S.T.[™] are two patented tools that enable identification of relevant human antibodies and disease targets during the discovery phase. The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of the new drug, and provide BioInvent the right to milestone payments and royalties on sales. These partners include Bayer Pharma, Daiichi Sankyo, Mitsubishi Tanabe and Servier. More information is available at www.bioinvent.com.

For further information, please contact:

Michael Oredsson
President and CEO
+46 (0)46 286 85 67
+46 (0)707 16 89 30
michael.oredsson@bioinvent.com

BioInvent International AB (publ)

Co. reg. No. 556537-7263

Visiting address: Sölvegatan 41

Mailing address: 223 70 LUND

Phone: +46 (0)46 286 85 50

info@bioinvent.com

www.bioinvent.com

Legal disclaimer

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.30 a.m. CET, on 11 November, 2013.